![Robert Zeldin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Zeldin
Technik-/Wissenschafts-/F&E-Leiter bei
MEIRAGTX HOLDINGS PLC
Vermögen: 2 Mio $ am 30.06.2026
Profil
Robert K.
Zeldin is currently Chief Medical Officer at MeiraGTx Holdings Plc since 2020.
Former positions include Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc. from 2018 to 2019; Chief Medical Officer at Immunovant, Inc. from 2019 to 2020; Chief Medical Officer at Ablynx NV from 2015 to 2018; Senior Vice President-Global Clinical Development at Stallergenes SAS from 2011 to 2015; Vice President at Novartis Pharmaceuticals Corp.
from 2005 to 2010; and Medical Officer roles at the US Food & Drug Administration and the Center for Biologics Evaluation & Research.
Education includes undergraduate studies at The Johns Hopkins University and a doctorate from Tufts University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MEIRAGTX HOLDINGS PLC 0,19 % | 25.06.2026 | 171.801 ( 0,19 % ) | 2 Mio $ | 30.06.2026 |
Aktive Positionen von Robert Zeldin
| Unternehmen | Position | Beginn |
|---|---|---|
| MEIRAGTX HOLDINGS PLC | Technik-/Wissenschafts-/F&E-Leiter | 05.08.2020 |
Ehemalige bekannte Positionen von Robert Zeldin
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOVANT, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2020 |
| ACCELERON PHARMA INC. | Technik-/Wissenschafts-/F&E-Leiter | 05.04.2019 |
| ABLYNX | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2018 |
| STALLERGENES | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Corporate Officer/Principal | 01.01.2010 |
Ausbildung von Robert Zeldin
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
68
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products used for the treatment of allergy-related respiratory diseases | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Develops and produces antibodies | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Health Technology |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
Center for Biologics Evaluation & Research
 Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Engages in conducting research to promote safe and appropriate use of biological products | Commercial Services |
Tufts University School of Medicine
 Tufts University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MeiraGTx Holdings Plc
 MeiraGTx Holdings Plc BiotechnologyHealth Technology Develops and manufactures genetic medicines | Health Technology |
Immunovant, Inc.
 Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
